Mesoblast Secures Medicaid Coverage for Ryoncil, Expanding Access for Pediatric Patients

Mesoblast Limited ( (AU:MSB) ) just unveiled an announcement.

Mesoblast Limited has announced its entry into the Medicaid National Drug Rebate Agreement with the U.S. Centers for Medicare & Medicaid Services for its product Ryoncil, providing access to children covered by Medicaid with steroid-refractory acute graft versus host disease (SR-aGvHD). This development marks a significant commercial milestone for Mesoblast, as it ensures that Ryoncil is available to all U.S. children with SR-aGvHD, regardless of their insurance status, potentially enhancing the company’s market position and impact on stakeholders.

More about Mesoblast Limited

Mesoblast Limited is a global leader in developing allogeneic cellular medicines for severe inflammatory conditions. The company specializes in mesenchymal lineage cell therapy technology, which addresses inflammation by releasing anti-inflammatory factors. Mesoblast’s flagship product, Ryoncil, is the first FDA-approved mesenchymal stromal cell therapy for treating pediatric steroid-refractory acute graft versus host disease (SR-aGvHD). The company is also advancing treatments for other inflammatory diseases and has established partnerships in Japan, Europe, and China.

YTD Price Performance: -37.73%

Average Trading Volume: 244,610

Technical Sentiment Signal: Sell

Current Market Cap: $1.62B

Learn more about MSB stock on TipRanks’ Stock Analysis page.